NICE Clears Pradaxa For Stroke Prevention, Rejects Appeal By NHS Budget Holders
This article was originally published in The Pink Sheet Daily
Following a failed appeal by regional NHS payers worried about its cost, Boehringer Ingelheim's Pradaxa is finally recommended by the U.K.'s cost watchdog, NICE, for preventing stroke associated with atrial fibrillation.
You may also be interested in...
NICE has given the thumbs up to Boehringer Ingelheim's Pradaxa in deep vein thrombosis and pulmonary embolism, which means the drug is now set to battle Bayer's Xarelto for market share in this indication.
Bayer’s Xarelto has made it into the NHS in England after its NICE recommendation went unchallenged, prompting a head to head battle with Boehringer Ingelheim’s Pradaxa.
It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.